NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
Complete the form below to unlock access to ALL audio articles.
Nanobiotix was judged as the company, outside of the CAC 40, that achieved the most successful and most promising IPO of the year. The Company came first in this category for successfully meeting the main criteria: corporate profile, leadership in its business activity and financial health.
“It is an honor to receive this award from the Investor Awards panel,” said Laurent Levy, CEO and co-founder of Nanobiotix. “This award reflects the success of the Nanobiotix IPO in October 2012, where many investors showed an interest in our breakthrough technology in nanomedicine for local cancer treatment. We remain focused on the clinical development of our products, which positions us as a leader in nanomedicine. We are also preparing for the challenges around the marketing of our lead product, NBTXR3, which could occur in 2017.”
This prize was awarded by Boursorama and Morningstar that jointly organize the largest survey that selects listed companies by individual and professional investors’ preferences.
The online survey was conducted with investors by OpinionWay in May 2013. In total, more than 40,000 votes were collected (two-thirds of individuals and a third of professionals).
